EP 100

Drug Profile

EP 100

Alternative Names: EP-100

Latest Information Update: 12 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Esperance Pharmaceuticals
  • Class Antineoplastics; Peptides
  • Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I Solid tumours

Most Recent Events

  • 12 Apr 2016 Phase-II development is ongoing in USA (IV)
  • 24 Aug 2015 Esperance Pharmaceuticals and MD Anderson Cancer Center agree to and co-develop EP 100 in USA for Breast and ovarian cancer
  • 14 Jun 2015 Esperance plans a phase-III trial for Ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top